1. Home
  2. ABT vs NVO Comparison

ABT vs NVO Comparison

Compare ABT & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABT

Abbott Laboratories

HOLD

Current Price

$95.58

Market Cap

183.3B

Sector

Health Care

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$40.42

Market Cap

166.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABT
NVO
Founded
1888
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.3B
166.1B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ABT
NVO
Price
$95.58
$40.42
Analyst Decision
Strong Buy
Hold
Analyst Count
20
11
Target Price
$130.95
$51.00
AVG Volume (30 Days)
8.4M
13.1M
Earning Date
04-16-2026
05-06-2026
Dividend Yield
2.60%
3.17%
EPS Growth
N/A
N/A
EPS
3.72
N/A
Revenue
$44,328,000,000.00
N/A
Revenue This Year
$10.75
N/A
Revenue Next Year
$8.10
$3.88
P/E Ratio
$26.01
$13.60
Revenue Growth
5.67
N/A
52 Week Low
$93.92
$35.12
52 Week High
$137.49
$81.44

Technical Indicators

Market Signals
Indicator
ABT
NVO
Relative Strength Index (RSI) 28.54 59.23
Support Level N/A $35.49
Resistance Level $103.84 $50.30
Average True Range (ATR) 2.21 1.02
MACD -0.40 0.74
Stochastic Oscillator 16.15 84.15

Price Performance

Historical Comparison
ABT
NVO

About ABT Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: